Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.36 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.35 |
| ▸ | EIF4EBP1 | Q13541 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ITK | Q08881 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6503556 | 0.89 | PPARG (0.42) | ALOX5APPPARGSMN1; SMN2NPC1RAB9A | |
| SCHEMBL6488966 | 0.84 | RXRA (0.41) | ALOX5APPIK3C2BDCTPP1PPARGSMN1; SMN2 | |
| SCHEMBL6490645 | 0.84 | PTGDR (0.44) | ALOX5APPIK3C2BDCTPP1PPARGSMN1; SMN2 | |
| SCHEMBL6496733 | 0.84 | ALOX5AP (0.47) | ALOX5APPIK3C2BDCTPP1PPARGSMN1; SMN2 | |
| SCHEMBL6489339 | 0.82 | LMNA (0.37) | PIK3C2BDCTPP1PPARGSMN1; SMN2LMNA | |
| SCHEMBL6492014 | 0.82 | SIRT2 (0.42) | PPARG | |
| SCHEMBL6489563 | 0.82 | SMN1; SMN2 (0.52) | ALOX5APPIK3C2BDCTPP1PPARGSMN1; SMN2 | |
| SCHEMBL6923139 | 0.82 | ALDH1A1 (0.38) | ALOX5APPIK3C2BDCTPP1PPARGSMN1; SMN2 | |
| SCHEMBL6490261 | 0.82 | CYP1A2 (0.42) | ALOX5APSMN1; SMN2RAB9ALMNA | |
| SCHEMBL6497678 | 0.81 | PTPN11 (0.46) | PPARGEIF4EBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | ALOX5AP 4663/4885PIK3C2B 2433/4885DCTPP1 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.